Table 2. Comparison of concomitant medications and comorbidities before anthracycline treatment between the subgroups stratified according to cardiotoxicity during follow-up.

Characteristic	Without cardiotoxicityn (%)	With cardiotoxicityn (%)	p-value (Fisher's exact test)
Diabetes	6 (9.8%)	3 (21.4%)	0.35
CAD	3 (4.9%)	0 (0.0%)	0.41
Hypertension	35 (57.4%)	7 (50.0%)	0.77
SCORE risk (mean ± SD) (median)	5.2 ± 3.0 (6)	3.4 ± 2.4 (5)	0.04
Drugs
β-blockers	16 (28.1%)	3 (21.4%)	0.75
ACE-I	12 (19.7%)	4 (28.6%)	0.48
Diuretics	11 (19.3%)	4 (28.6%)	0.48
Ca-blockers	10 (17.5%)	0 (0.0%)	0.19
Sartans	13 (22.8%)	1 (7.1%)	0.27
Sulfonylureas	3 (4.9%)	2 (14.3%)	0.23
Biguanides	3 (4.9%)	1 (7.1%)	0.57
Insulin	2 (3.3%)	1 (7.1%)	0.47
Dexamethasone	15 (24.6%)	5 (35.7%)	0.52
Smoking	27 (45.0%)	4 (28.6%)	0.37

ACE-I, angiotensin-converting-enzyme inhibitor; Ca, calcium; CAD, coronary artery disease; SCORE, systemic coronary risk evaluation.